PPARG and fatty liver disease: In high-glucose + palmitate-induced HepG2 cells, ZQC-containing serum and the PPARγ agonist GW1929 were applied to assess gluconeogenic and lipogenic proteins.<h4>Results</h4>ZQC improved glycemia, insulin resistance, lipid profiles, and hepatic steatosis.